{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,12,18]],"date-time":"2024-12-18T05:31:39Z","timestamp":1734499899499,"version":"3.30.2"},"reference-count":30,"publisher":"Ubiquity Press, Ltd.","license":[{"start":{"date-parts":[[2024,12,17]],"date-time":"2024-12-17T00:00:00Z","timestamp":1734393600000},"content-version":"unspecified","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["TOHM"],"abstract":"<jats:p>Background: Essential tremor (ET) is among the most common movement disorders, yet there are few treatment options. Medications have limited efficacy and adverse effects; thus, patients often discontinue pharmacotherapy or take several medications in combination. We evaluated the economic correlates (healthcare resource utilization [HCRU] and costs) and comorbidities among adults with and without ET and among subgroups of patients with ET prescribed 0 to \u22653 ET medications.\nMethod: This was a retrospective cohort study using claims data from the Merative Market Scan Research Databases (1\/1\/2017\u20131\/31\/2022). Patients were categorized as commercially insured (22\u2013&lt;65 years) or Medicare (\u226565 years) and stratified into 3 subgroups: patients with untreated ET, patients with treated ET, and non-ET patients. The index date was the date of first ET diagnosis or a random date (non-ET patients); post-index follow-up was 24 months.\nResults: There were 32,984 ET patients (n = 22,641 commercial; n = 10,343 Medicare) and 7,588,080 non-ET patients (n = 7,158,471 commercial; n = 429,609 Medicare). ET patients in both commercial and Medicare populations filled a numerically greater number of unique medications, had a higher numerical prevalence of comorbidities (ie, anxiety, depression, falls), and had numerically greater HCRU and costs than non-ET patients. Most of these numerical trends increased commensurately with increasing number of ET medications.\nConclusions: Compared to non-ET patients, ET patients have higher healthcare costs and utilization, which positively correlated with the number of ET medications. ET patients often have numerically more comorbidities compared to non-ET patients. This analysis demonstrates the medical complexity of ET patients and calls attention to the need for additional therapeutic options.<\/jats:p>","DOI":"10.5334\/tohm.973","type":"journal-article","created":{"date-parts":[[2024,12,17]],"date-time":"2024-12-17T12:39:23Z","timestamp":1734439163000},"page":"62","source":"Crossref","is-referenced-by-count":0,"title":["Clinical and Economic Correlates of Pharmacotherapy in Patients with Essential Tremor"],"prefix":"10.5334","volume":"14","author":[{"given":"Rajesh","family":"Pahwa","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kalea","family":"Colletta","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Donald","family":"Higgins","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bridgette Kanz","family":"Schroader","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Brian M.","family":"Davis","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Liana","family":"Hennum","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Elan D.","family":"Louis","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"3285","published-online":{"date-parts":[[2024,12,17]]},"reference":[{"key":"key20241217123915_B1","doi-asserted-by":"crossref","first-page":"28","DOI":"10.5334\/tohm.632","article-title":"How common is essential tremor? Update on the worldwide prevalence of essential tremor","volume":"11","year":"2021","journal-title":"Tremor Other Hyperkinet Mov (N Y)"},{"issue":"6","key":"key20241217123915_B2","doi-asserted-by":"crossref","first-page":"761","DOI":"10.1002\/ana.1022","article-title":"Risk of tremor and impairment from tremor in relatives of patients with essential tremor: a community-based family study","volume":"49","year":"2001","journal-title":"Ann Neurol"},{"issue":"2","key":"key20241217123915_B3","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1016\/S0002-9343(03)00259-6","article-title":"Essential tremor: differential diagnosis and current therapy","volume":"115","year":"2003","journal-title":"Am J Med"},{"issue":"962","key":"key20241217123915_B4","doi-asserted-by":"crossref","first-page":"756","DOI":"10.1136\/pgmj.2005.032979","article-title":"Differential diagnosis of common tremor syndromes","volume":"81","year":"2005","journal-title":"Postgrad Med J"},{"issue":"15","key":"key20241217123915_B5","doi-asserted-by":"crossref","first-page":"2281","DOI":"10.1002\/mds.22777","article-title":"Isolated head tremor: part of the clinical spectrum of essential tremor? Data from population-based and clinic-based case samples","volume":"24","year":"2009","journal-title":"Mov Disord"},{"key":"key20241217123915_B6","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1016\/B978-0-444-63233-3.00015-4","article-title":"Essential tremor","volume":"147","year":"2018","journal-title":"Handb Clin Neurol"},{"issue":"2","key":"key20241217123915_B7","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1159\/000356351","article-title":"\u2018Essential tremor\u2019 or \u2018the essential tremors\u2019: is this one disease or a family of diseases?","volume":"42","year":"2014","journal-title":"Neuroepidemiology"},{"issue":"10","key":"key20241217123915_B8","doi-asserted-by":"crossref","first-page":"1721","DOI":"10.1212\/01.WNL.0000161852.70374.01","article-title":"Neurological Disorders in Central Spain (NEDICES) Study Group. Incidence of essential tremor in three elderly populations of central Spain","volume":"64","year":"2005","journal-title":"Neurology"},{"issue":"19","key":"key20241217123915_B9","doi-asserted-by":"crossref","first-page":"1752","DOI":"10.1212\/WNL.0b013e318236f0fd","article-title":"Evidence-based guideline update: treatment of essential tremor: report of the Quality Standards subcommittee of the American Academy of Neurology","volume":"77","journal-title":"Neurology"},{"issue":"7","key":"key20241217123915_B10","doi-asserted-by":"crossref","first-page":"950","DOI":"10.1002\/mds.27700","article-title":"MDS evidence-based review of treatments for essential tremor","volume":"34","year":"2019","journal-title":"Mov Disord"},{"issue":"9","key":"key20241217123915_B11","doi-asserted-by":"crossref","first-page":"604","DOI":"10.1016\/j.parkreldis.2010.07.011","article-title":"Survey of medication usage patterns among essential tremor patients: movement disorder specialists vs. general neurologists","volume":"16","year":"2010","journal-title":"Parkinsonism Relat Disord"},{"key":"key20241217123915_B12","first-page":"100101","article-title":"Exploring essential tremor: Results from a large online survey","volume":"5","year":"2021","journal-title":"Clin Park Relat Disord"},{"issue":"12","key":"key20241217123915_B13","doi-asserted-by":"crossref","first-page":"5546","DOI":"10.1007\/s12325-022-02318-8","article-title":"The hidden burden of disease and treatment experiences of patients with essential tremor: a retrospective claims data analysis","volume":"39","year":"2022","journal-title":"Adv Ther"},{"key":"key20241217123915_B14","unstructured":"Lyons K, Ott KR, Shill H. International Essential Tremor Foundation: essential tremor in adult patients. Accessed August 31, 2023. https:\/\/www.guidelinecentral.com\/guideline\/502775\/pocket-guide\/502776\/."},{"key":"key20241217123915_B15","unstructured":"IBM Watson Health. IBM MarketScan Research Databases for life sciences researchers. Accessed August 31, 2023. https:\/\/www.ibm.com\/downloads\/cas\/OWZWJ0QO."},{"key":"key20241217123915_B16","first-page":"29","article-title":"Medical treatment of essential tremor","volume":"6","year":"2014","journal-title":"J Cent Nerv Syst Dis"},{"issue":"12","key":"key20241217123915_B17","doi-asserted-by":"crossref","first-page":"2008","DOI":"10.1212\/01.WNL.0000163769.28552.CD","article-title":"Practice parameter: therapies for essential tremor: report of the Quality Standards Subcommittee of the American Academy of Neurology","volume":"64","year":"2005","journal-title":"Neurology"},{"issue":"2","key":"key20241217123915_B18","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1016\/S1474-4422(10)70322-7","article-title":"Treatment of patients with essential tremor","volume":"10","year":"2011","journal-title":"Lancet Neurol"},{"issue":"10","key":"key20241217123915_B19","doi-asserted-by":"crossref","first-page":"904","DOI":"10.1136\/jnnp.42.10.904","article-title":"Beta-adrenoreceptor antagonists in essential tremor","volume":"42","year":"1979","journal-title":"J Neurol Neurosurg Psychiatry"},{"issue":"5","key":"key20241217123915_B20","first-page":"547","article-title":"Atenolol vs. propranolol in essential tremor. A controlled, quantitative study","volume":"66","year":"1982","journal-title":"Acta Neurol Scand"},{"issue":"3","key":"key20241217123915_B21","doi-asserted-by":"crossref","first-page":"714","DOI":"10.1007\/s00415-012-6628-x","article-title":"Treatment of essential tremor: a systematic review of evidence and recommendations from the Italian Movement Disorders Association","volume":"260","journal-title":"J Neurol"},{"issue":"4","key":"key20241217123915_B22","first-page":"Cd009683","article-title":"Topiramate for essential tremor","volume":"4","year":"2017","journal-title":"Cochrane Database Syst Rev"},{"issue":"4","key":"key20241217123915_B23","first-page":"188","article-title":"Charlson Comorbidity Index: ICD-9 update and ICD-10 translation","volume":"12","year":"2019","journal-title":"Am Health Drug Benefits"},{"issue":"1","key":"key20241217123915_B24","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1186\/s12877-017-0621-2","article-title":"What is polypharmacy? A systematic review of definitions","volume":"17","year":"2017","journal-title":"BMC Geriatr"},{"issue":"2","key":"key20241217123915_B25","doi-asserted-by":"crossref","first-page":"37","DOI":"10.36469\/jheor.2022.37307","article-title":"Multiple comorbidities, psychiatric disorders, healthcare resource utilization and costs among adults with essential tremor: a retrospective observational study in a large US commercially insured and Medicare Advantage population","volume":"9","year":"2022","journal-title":"J Health Econ Outcomes Res"},{"key":"key20241217123915_B26","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1159\/000530535","article-title":"Odds of medical comorbidities in essential tremor: Retrospective analysis of a large claims database in the United States","volume":"57","year":"2023","journal-title":"Neuroepidemiology"},{"issue":"2","key":"key20241217123915_B27","first-page":"S636","article-title":"Prevalence of essential tremor among patients with commercial or Medicare health insurance in the United States 2010\u20132018","volume":"23","year":"2020","journal-title":"Value Health"},{"key":"key20241217123915_B28","unstructured":"US Pharmacist. Polypharmacy. Accessed August 31, 2023. https:\/\/www.uspharmacist.com\/article\/polypharmacy."},{"key":"key20241217123915_B29","unstructured":"Health Research Funding. 12 incredible polypharmacy statistics. Accessed August 31, 2023. https:\/\/healthresearchfunding.org\/polypharmacy-statistics\/."},{"issue":"1","key":"key20241217123915_B30","doi-asserted-by":"crossref","first-page":"648","DOI":"10.1186\/s12877-021-02594-z","article-title":"Prevalence of potentially harmful multidrug interactions on medication lists of elderly ambulatory patients","volume":"21","journal-title":"BMC Geriatr"}],"container-title":["Tremor and Other Hyperkinetic Movements"],"original-title":[],"link":[{"URL":"https:\/\/account.tremorjournal.org\/index.php\/up-j-tohm\/article\/download\/973\/1945","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/account.tremorjournal.org\/index.php\/up-j-tohm\/article\/download\/973\/1946","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/account.tremorjournal.org\/index.php\/up-j-tohm\/article\/download\/973\/1947","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/account.tremorjournal.org\/index.php\/up-j-tohm\/article\/download\/973\/1948","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/account.tremorjournal.org\/index.php\/up-j-tohm\/article\/download\/973\/1945","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,12,17]],"date-time":"2024-12-17T12:49:18Z","timestamp":1734439758000},"score":1,"resource":{"primary":{"URL":"https:\/\/account.tremorjournal.org\/index.php\/up-j-tohm\/article\/view\/973"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,12,17]]},"references-count":30,"URL":"https:\/\/doi.org\/10.5334\/tohm.973","relation":{},"ISSN":["2160-8288"],"issn-type":[{"value":"2160-8288","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,12,17]]}}}